You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Novartis’ canakinumab fails to improve overall survival in lung cancer trial

Novartis has announced that its interleukin-1beta (IL-1β) inhibitor canakinumab failed to hit the primary endpoint of overall survival in a Phase III non-small cell lung cancer (NSCLC) trial.